NextCure, Inc. (NASDAQ: NXTC) shares slumped to close down 53% to $39.02. Shares of the company initially surged over 200% last week following the release of its abstract of NC318 for the SITC conference. However, updated data released at the conference noted that there were no further responses in additional patients with non-small cell lung cancer (NSCLC).

ASLAN Pharmaceuticals (NASDAQ:ASLN) announced top-line data from its Phase 2/3 TreeTopp trial of varlitinib in patients with biliary tract cancer, did not met the primary endpoints of progression-free survival (PFS) and overall response rate (ORR). Shares closed down 68% to $0.67.

Lipocine Inc. (NASDAQ: LPCN) announced it received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for Tlando in males with conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. The CRL identified the efficacy trial did not meet the three secondary endpoints for maximal testosterone concentrations. Shares plunged to close down 71% to $0.80.

MyoKardia, Inc. (Nasdaq: MYOK) announced top-line data from its Phase 2 MAVERICK-HCM trial of mavacamten in patients with non-obstructive hypertrophic cardiomyopathy (HCM). The company noted the trial met its primary objective of establishing safety and tolerability of mavacamten in non-obstructive HCM over a treatment period of 16 weeks. However, shares sold off on safety concerns with five patients exhibiting ejection fraction reductions (amount of blood that is pumped out of the ventricles with each contraction) below the protocol-defined threshold of 45%. Shares closed down 8% to $55.45.

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) and Menlo Therapeutics Inc. (Nasdaq: MNLO) announced a merger of the two companies where Foamix shareholders will own approximately 59% of the combined company and Menlo shareholders will own approximately 41%. Shares of Foamix closed down 20% to $3.48, while Menlo shares closed 7% lower to $4.85.

Kadmon Holdings, Inc. (NYSE: KDMN) shares are trading up 21% after hours to $3.63 following its announcement interim data from its of ROCKstar trial of KD025 in patients with chronic graft-versus-host disease (cGVHD), met the primary endpoint of Overall Response Rate (ORR).

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume

ADVANCERS:

Cabaletta Bio, Inc. (CABA): $13.92; +25%.

Jounce Therapeutics, Inc. (JNCE): $4.70; +16%.

Fulcrum Therapeutics, Inc. (FULC): $7.92; +13%.

Constellation Pharmaceuticals, Inc. (CNST): $34.38; +11%.

Aquestive Therapeutics, Inc. (AQST): $5.99; +11%.

DECLINERS:

RAPT Therapeutics, Inc. (RAPT): $19.60; -30%.

Assembly Biosciences, Inc. (ASMB): $14.48; -15%.

FibroGen, Inc. (FGEN): $35.40; -15%.

Celsion Corporation (CLSN): $1.24; -14%.

Ocular Therapeutix, Inc. (OCUL): $2.93; -12%.

Pipeline updates below: